Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,006,650 | 5,024,354 | 2,803,963 | 5,494,152 | 2,269,975 |
| Marketable Securities | 1,087,052 | 1,553,785 | 1,943,078 | 880,182 | 2,461,955 |
| Receivables | 13,502,760 | 14,465,610 | 13,056,720 | 12,186,240 | 12,675,030 |
| Inventories | 7,512,922 | 7,439,126 | 6,943,669 | 6,046,558 | 5,923,105 |
| Other current assets | -4 | 5 | 0 | -2 | -5 |
| TOTAL | $26,109,380 | $28,482,880 | $24,747,430 | $24,607,130 | $23,330,060 |
| Non-Current Assets | |||||
| PPE Net | 31,548,430 | 30,262,010 | 27,493,290 | 24,322,250 | 23,560,760 |
| Investments And Advances | 379,560 | 426,735 | 401,240 | 380,970 | 388,165 |
| Intangibles | 19,690,023 | 16,691,520 | 16,406,420 | 15,433,380 | 16,108,050 |
| Other Non-Current Assets | 4,467,967 | 4,361,155 | 4,287,090 | 4,277,030 | 4,153,235 |
| TOTAL | $56,085,980 | $51,741,420 | $48,588,040 | $44,413,630 | $44,210,210 |
| Total Assets | $82,195,360 | $80,224,300 | $73,335,470 | $69,020,760 | $67,540,270 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,819,374 | 1,884,524 | 1,819,572 | 3,162,474 | 1,901,385 |
| Accounts payable and accrued liabilities | 2,991,361 | 3,743,366 | 4,290,133 | 2,762,174 | 4,182,670 |
| Other current liabilities | 26,566,160 | 27,574,910 | 22,879,790 | 25,204,270 | 24,048,690 |
| TOTAL | $32,651,080 | $36,700,460 | $31,564,100 | $33,316,110 | $31,541,560 |
| Non-Current Liabilities | |||||
| Long Term Debt | 18,007,670 | 13,965,590 | 13,279,090 | 13,589,340 | 13,002,730 |
| Other Non-Current Liabilities | 1,156,995 | 1,501,171 | 1,439,478 | 1,339,044 | 1,403,750 |
| TOTAL | $20,165,570 | $16,918,130 | $16,208,540 | $16,156,660 | $15,193,250 |
| Total Liabilities | $52,816,650 | $53,618,590 | $47,772,630 | $49,472,770 | $46,734,800 |
| Shareholders' Equity | |||||
| Common Shares | 67,524 | 69,844 | 67,837 | 62,931 | 64,670 |
| Retained earnings | 29,568,120 | 26,391,640 | 25,013,300 | 19,375,710 | 20,944,960 |
| Other shareholders' equity | -256,934 | 144,226 | 481,703 | 109,349 | -204,160 |
| TOTAL | $29,378,710 | $26,605,710 | $25,562,840 | $19,547,990 | $20,805,470 |
| Total Liabilities And Equity | $82,195,360 | $80,224,300 | $73,335,470 | $69,020,760 | $67,540,270 |